About us
Where, what, why and who?
Where?
We are a leukaemia research group based in the department of , , at the 探花精选. We are also part of the at Sussex, a network of collborative research groups with shared interests in normal and malignant haematology across the and .
探花精选 Falmer campus
What?
Our research investigates the role of a signal transduction cascade, , in both normal blood development and haematological malignancy. Ultimately we want to understand how this cell signalling pathway converts normal healthy blood cells into malignant leukaemia cells with the aim of designing novel therapeutic interventions for patients. Please see Our Research section to find out more about what we do.
Normal bone marrow aspirate from a healthy donor AML bone marrow aspirate with leukaemia blasts
Why?
Specifically we focus on a type of blood cancer called According to , there are around 3,200 new cases of AML per year in the UK which affects both adults and children. Survival rates for this devastating disease have improved markedly over the past 50 years, however treatment of specific patient subsets continues to be a challenge, particularly since chemotherapies from the 1960-70's remain the main treatment strategy. As we enter a new era of patient tailorised medicine, hope now lies with more highly targeted, better tolerated, molecular therapies that induce long-lasting remissions.
UK incidence of AML (Cancer Research UK)
Who?
At present, we are a team of 5 mixed staff and students. Please see Meet the Team pages for further information on individual group members. The group is led by .
Dr. Morgan completed his BSc in Biomedical Science at the University of Portsmouth before completing a PhD in Experimental Haematology at . His thesis examined the role of a Wnt signalling protein (γ-catenin) in AML under the supervision of Professors Alan Burnett, Richard Darley and Alex Tonks. From here Rhys joined the at the University of Bristol to pursue his interests in signal transduction and cancer biology. Under the supervision of Professors Christos Paraskeva and Ann Williams he undertook post-doctoral studies investigating the role of the stem cell marker LGR5 and Wnt/EGF signal transduction in colorectal cancer.
Whilst at Bristol, Rhys was awarded a prestigious Kay Kendall Leukaemia Fund (KKLF) Junior Fellowship in 2016 targeting Wnt/β-catenin signalling in AML which remains his primary research focus. In 2018 Rhys moved his fellowship to the at the 探花精选 to establish his own leukaemia research laboratory and is now a in the department of Biochemistry & Biomedicine.
In 2020 Rhys joined as a member of the Research & Review Committee. Dr. Morgan is also an advocate of stem cell donation and continues to work with and their sister organisation (student led recruitment on UK university campuses) to promote awareness and registration onto the bone marrow register. Read about Rhys's stem cell donation which reached .
Dr. Rhys Morgan donating stem cells in May 2016
